玻璃体腔注射康柏西普在重度非增殖性糖尿病视网膜病变治疗中的应用效果  

Efficacy of intravitreal injection of Compaplexil in the treatment of severe non-proliferative diabetic retinopathy

作　　者：邓洁 Deng Jie(Tianjin Baodi Hospital,Tianjin 301800,China)

机构地区：[1]天津市宝坻区人民医院,天津301800

出　　处：《首都食品与医药》2024年第19期83-85,共3页Capital Food Medicine

摘　　要：目的探讨玻璃体腔注射康柏西普在重度非增殖性糖尿病视网膜病变(NPDR)治疗中的应用效果。方法回顾性分析2022年2月-2023年12月100例重度NPDR患者的临床资料,按治疗方法分为两组,对照组(n=44)采用激光治疗,观察组(n=56)在激光治疗基础上联合玻璃体腔注射康柏西普,比较两组疗效。结果观察组治疗后1个月、2个月、3个月及末次随访的CMT均明显小于对照组(P<0.05)。观察组在治疗后3个月的CAT明显小于对照组(P<0.05)。观察组视网膜病变疗效、BCVA疗效明显优于对照组(P<0.05)。结论玻璃体腔注射康柏西普治疗可有效减轻黄斑水肿,减轻视网膜病变,与激光治疗联合,能更有效改善重度NPDR患者的视功能预后。Objective To investigate the effect of intravitreal injection of Compaplexil in the treatment of severe non-proliferative diabetic retinopathy(NPDR).Methods The clinical data of 100 patients with severe NPDR from February 2022 to December 2023 were retrospectively analyzed,and divided into two groups according to treatment methods:the control group(n=44)received laser treatment,and the observation group(n=56)received laser treatment combined with intravitreal injection of Compaplexil,and the efficacy of the two groups was compared.Results The CMT of observation group at 1 month,2 months,3 months and the last follow-up after treatment was significantly lower than that of control group(P<0.05).The CAT of the observation group was significantly lower than that of the control group 3 months after treatment(P<0.05).The curative effect of retinopathy and BCVA in the observation group were significantly better than those in the control group(P<0.05).Conclusion Intravitreal injection of Compaercept can effectively reduce macular edema and retinopathy,and the combination with laser therapy can more effectively improve the visual function prognosis of patients with severe NPDR.

关 键 词：糖尿病视网膜病变 非增殖性 康柏西普 黄斑中心厚度 黄斑区视网膜平均厚度 

分 类 号：R587.2[医药卫生—内分泌]